¼¼°èÀÇ Åõ·¿ ÁõÈıº Ä¡·á ½ÃÀå
Tourette Syndrome Treatment
»óǰÄÚµå : 1788375
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 186 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,156,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,469,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Åõ·¿ ÁõÈıº Ä¡·á ½ÃÀåÀº 2030³â±îÁö 31¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 23¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Åõ·¿ ÁõÈıº Ä¡·á ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 5.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ç×Á¤½Åº´¾àÀº CAGR 4.1%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 20¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñÇ×Á¤½Åº´¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 7.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 6¾ï 2,600¸¸ ´Þ·¯, Áß±¹Àº CAGR 7.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Åõ·¿ ÁõÈıº Ä¡·á ½ÃÀåÀº 2024³â¿¡ 6¾ï 2,600¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 7.9%·Î, 2030³â±îÁö 6¾ï 990¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.5%¿Í 5.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Åõ·¿ ÁõÈıº Ä¡·á ½ÃÀåÀÇ µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¶Ñ·¿ ÁõÈıº Ä¡·á´Â ¸ÂÃãÇü ÀÇ·á¿Í ½Å°æÁ¶Àý·Î ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

¶Ñ·¿ÁõÈıº(TS)Àº ¹Ýº¹ÀûÀÌ°í ºÒ¼öÀÇÀûÀΠƽ°ú ¹ß¼ºÀ» Ư¡À¸·Î ÇÏ´Â ½Å°æÁúȯÀ¸·Î, ÁÖ·Î ¾î¸° ½ÃÀý¿¡ ¹ßº´ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Á¤È®ÇÑ ¿øÀÎÀº ¹àÇôÁöÁö ¾Ê¾ÒÁö¸¸, ¿¬±¸¿¡ µû¸£¸é À¯ÀüÀû, ½Å°æÇÐÀû, ȯ°æÀû ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î °ü¿©ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ¿ª»çÀûÀ¸·Î Ä¡·á ¿É¼ÇÀº Çൿġ·á¿Í µµÆÄ¹Î ±æÇ×Á¦, ¥á-adrenergic agonist¿Í °°Àº ¾à¸®ÇÐÀû ÁßÀç¿¡ ±¹ÇÑµÇ¾î ¿Ô½À´Ï´Ù. ÇÏÁö¸¸ ¸ÂÃãÇü ÀÇ·á, ½Å°æÁ¶Àý±â¼ú, À¯ÀüÀÚÄ¡·á°¡ °­Á¶µÇ¸é¼­ Ä¡·á¹ýÀº Å©°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. ³ú½ÉºÎÀڱؿä¹ý(DBS)°ú °æµÎ°³ÀÚ±âÀڱؿä¹ý(TMS)Àº ±âÁ¸ ¾à¹° Ä¡·áÀÇ ºÎÀÛ¿ë ¾øÀÌ Áõ»ó Á¶ÀýÀ» °³¼±ÇÏ´Â À¯¸Á ºñħ½ÀÀû ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Áø´Ü Áö¿¬, Áõ»ó ÁßÁõµµ ÆíÂ÷, Ä¡·á Á¢±Ù¼º Á¦ÇÑ µîÀÇ ¹®Á¦´Â ¿©ÀüÈ÷ ³²¾ÆÀÖ½À´Ï´Ù. ½Å°æÁ¤½ÅÀÇÇÐ ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó Ç¥ÀûÄ¡·á¿Í µðÁöÅÐ Ä¡·áÀÇ ±â¼ú Çõ½ÅÀÌ ¶Ñ·¿ ÁõÈıº Ä¡·áÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô ÀçÁ¤ÀÇÇÒ ¼ö Àִ°¡?

Åõ·¿ ÁõÈıº Ä¡·á¸¦ ¹ßÀü½Ã۰í ÀÖ´Â ±â¼ú Çõ½ÅÀº ¾î¶² °ÍÀÌ Àִ°¡?

ÃÖ±Ù TS Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀº Á¤¹ÐÇÑ ½Å°æÁ¶Àý, AI ±â¹Ý Áø´Ü Åø, ¾à¹°À¯ÀüüÇп¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¿ø·¡ ÆÄŲ½¼º´À» À§ÇØ °³¹ßµÈ DBS´Â ÇöÀç TS¸¦ À§ÇØ ¿¬±¸µÇ°í ÀÖÀ¸¸ç, ºñÁ¤»óÀûÀÎ ½Å°æÈ¸·Î¸¦ Á¶ÀýÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. AI ±â¹Ý ÀÎÁöÇൿġ·á(CBT) ¾ÛÀº ¿ø°ÝÀ¸·Î ƽÀ» °ü¸®ÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á¸¦ ´õ¿í Ä£¼÷ÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. À¯ÀüÇÐÀû ¿¬±¸¸¦ ÅëÇØ TSÀÇ ÀáÀçÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿°¡ ¹àÇôÁö°í ÀÖÀ¸¸ç, ȯÀÚ °³°³Àο¡ ¸Â´Â Ç¥Àû Ä¡·áÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Ç½Ã°£ ¹ÙÀÌ¿ÀÇǵå¹é ¸ÞÄ¿´ÏÁòÀ» °®Ãá ¿þ¾î·¯ºí ±â±â°¡ µðÁöÅÐ Ä¡·áÁ¦·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ´º·ÎÇǵå¹é ¹× ½À°ü ¹ÝÀü ÈÆ·ÃÀ» ÅëÇØ ƽ Àå¾Ö °ü¸®¸¦ µ½°í ÀÖ½À´Ï´Ù.

Åõ·¿ ÁõÈıº Ä¡·á ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½Å°æ ¹ß´Þ Àå¾ÖÀÇ À¯º´·ü Áõ°¡, TS¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ºñħ½ÀÀû ½Å°æÁ¶ÀýÀÇ ¹ßÀüÀº Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÎ¸ð¿Í º¸È£ÀÚµéÀº ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á·Î ¾à¹° Ä¡·á ÀÌ¿ÜÀÇ ´ëü¿ä¹ýÀ» ¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çൿ ÁßÀç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Åõ·¿ ÁõÈıº Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å°æ ÀÚ±Ø Ä¡·áÀÇ ¹ßÀü, À¯ÀüÇÐ ¹× ½Å°æ»ý¹°ÇÐÀû ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸ Áõ°¡, ºñ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ È®´ë µîÀ¸·Î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Åõ·¿ ÁõÈıº¿¡ ´ëÇÑ ÀÌÇØ°¡ ÁøÀüµÊ¿¡ µû¶ó ÇâÈÄ Ä¡·á´Â °³º°È­µÈ ±â¼ú ±â¹Ý °³ÀÔ¿¡ ÃÊÁ¡À» ¸ÂÃâ °ÍÀ̸ç, À̴ ȯÀÚÀÇ °á°ú¿Í »îÀÇ ÁúÀ» Çâ»ó½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(Ç×Á¤½Åº´¾à, ºñÇ×Á¤½Åº´¾à)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Tourette Syndrome Treatment Market to Reach US$3.1 Billion by 2030

The global market for Tourette Syndrome Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Antipsychotics, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Non-Antipsychotics segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$626.0 Million While China is Forecast to Grow at 7.9% CAGR

The Tourette Syndrome Treatment market in the U.S. is estimated at US$626.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$609.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Tourette Syndrome Treatment Market Trends & Drivers Summarized

How Is Tourette Syndrome Treatment Advancing with Personalized Medicine and Neuromodulation?

Tourette Syndrome (TS) is a neurological disorder characterized by repetitive, involuntary tics and vocalizations, often appearing in childhood. While the exact cause remains unclear, research indicates a combination of genetic, neurological, and environmental factors. Historically, treatment options have been limited to behavioral therapy and pharmacological interventions, such as dopamine antagonists and alpha-adrenergic agonists. However, the growing emphasis on personalized medicine, neuromodulation techniques, and gene therapy is transforming the treatment landscape. Deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are emerging as promising non-invasive solutions for severe cases, offering improved symptom control without the side effects associated with traditional medications. However, challenges such as delayed diagnosis, variability in symptom severity, and limited treatment accessibility persist. As neuropsychiatric research advances, how will innovations in targeted therapies and digital therapeutics redefine the future of Tourette Syndrome treatment?

What Technological Innovations Are Advancing Tourette Syndrome Treatment?

Recent breakthroughs in TS treatment focus on precision neuromodulation, AI-driven diagnostic tools, and pharmacogenomics. DBS, originally developed for Parkinson’s disease, is now being explored for TS, helping to regulate abnormal neural circuits. AI-based cognitive behavioral therapy (CBT) apps are enabling remote tic management, making treatment more accessible. Genetic research is uncovering potential biomarkers for TS, paving the way for targeted therapies tailored to individual patients. Additionally, wearable devices with real-time biofeedback mechanisms are emerging as digital therapeutics, helping individuals manage tics through neurofeedback and habit-reversal training.

Why Is the Demand for Tourette Syndrome Treatment Increasing?

The increasing prevalence of neurodevelopmental disorders, growing awareness of TS, and advancements in non-invasive neuromodulation are driving demand for innovative treatments. Parents and caregivers are seeking alternative therapies beyond medication due to concerns over side effects. Additionally, the rising adoption of telemedicine and digital therapeutics is expanding access to behavioral interventions, further fueling market growth.

What Factors Are Driving the Growth of the Tourette Syndrome Treatment Market?

The market is expanding due to advancements in neurostimulation therapies, increasing research into genetic and neurobiological mechanisms, growing demand for non-pharmacological treatments, and expanding digital health solutions. As the understanding of Tourette Syndrome improves, future treatments will likely focus on personalized and technology-driven interventions, enhancing patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Tourette Syndrome Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Antipsychotics, Non-Antipsychotics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â